

Book Chapter

Prognostic Variables and 4-Year Survival Outcomes in CD20 Positive AIDS-Related Lymphoma in the Anti-retroviral Treatment Era: A Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa

Nadine Rapiti^{1*}, Nada Abdelatif² and Mahomed-Yunus S Moosa³

¹Department of Haematology, NHLS/University of KwaZulu Natal/King Edward VIII Hospital, South Africa

²Biostatistics Research Unit, South African Medical Research Council, South Africa

³Department of Infectious Diseases, University of KwaZulu-Natal, South Africa

***Corresponding Author:** Nadine Rapiti, Department of Haematology, NHLS/University of KwaZulu Natal/King Edward VIII Hospital, Durban, South Africa

Published **January 02, 2023**

This Book Chapter is a republication of an article published by Nadine Rapiti, et al. at PLoS ONE in September 2022. (Rapiti N, Abdelatif N, Moosa M-YS (2022) Prognostic variables and 4-year survival outcomes in CD20 Positive AIDS-Related Lymphoma in the Anti-retroviral treatment era: A Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa. PLoS ONE 17(9): e0272282.

<https://doi.org/10.1371/journal.pone.0272282>)

How to cite this book chapter: Nadine Rapiti, Nada Abdelatif, Mahomed-Yunus S Moosa. Prognostic Variables and 4-Year Survival Outcomes in CD20 Positive AIDS-Related Lymphoma

in the Anti-retroviral Treatment Era: A Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa. In: Tanja Sarenac, editor. Advances in Cancer Research. Wyoming, USA: Academic Reads. 2023.

© The Author(s) 2023. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ethical Approval and Consent to Participate: The study protocol was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (BE043/17) In October 2017. As the study was retrospective, there was no study-specific consent. All patients granted verbal or written consent prior to any investigation or treatment.

Consent for Publication: All authors consent to publication

Availability of Data and Material: All relevant data is within the article and additional data may be provided on request.

Acknowledgement: Dr Felicia Manickam for data collection and caring for patients in the study

Mrs Pam Pillay for electronic data capture

Doctors and nurses at the haematology clinic at King Edward VIII Hospital for caring for haematology patients in this study

National Health Laboratory Services and medical management at King Edward VIII Hospital for integrating laboratory and clinical haematology in KwaZulu-Natal.

Acknowledgements: Mrs Pam Pillay and Dr Felicia Manickam for data collection and electronic data capture.

The nurses and doctors at the haematology clinic and chemotherapy room at Edward VIII Hospital

National Health Laboratory Service and management at King Edward VIII hospital for integrating laboratory and clinical haematology care in the province.

Statement of Ethics: This study was approved by the Biomedical Research and Ethics Council in the University of KwaZulu-Natal ((BE043/17).

Abstract

Objective: To describe 4-year survival outcomes and assess the value of established and additional relevant variables to predict complete response (CR), four-year progression-free survival (PFS) and overall survival (OS) of CD20 positive AIDS-Related Lymphoma (ARL) treated with standard combination chemotherapy.

Method: We performed a retrospective review of patients diagnosed with CD20 positive ARL between 2006 and 2016. All patients over 12 years of age who received at least one cycle of combination chemotherapy with curative intent were included in the analysis. Variables assessed included the International Prognostic Index (IPI), age-adjusted-IPI, age, gender, B symptoms, extent of disease, functional performance status, CD4 cell count, viral load, concurrent ART with chemotherapy, rituximab inclusion, and number of chemotherapy cycles used. Kaplan-Meier survival curves for OS and PFS at 4 years were compared for IPI and aaIPI using the log-rank test. A Cox proportional hazards model was used to investigate the effects of prognostic variables for patients achieving OS and PFS at 4 years and logistic regression for patients achieving CR.

Results: A total of 102 patients were included in the analysis. At year four of follow-up, the OS was 50% (n=51) and PFS was 43% (n=44). Attaining a CR and male gender were significantly associated with improved 4-year OS (p<0.001 and p=0.028 respectively) and PFS (p<0.001 and 0.048 respectively). A viral load of < 50 copies/ml was associated with a higher complete response rate (aOR 6.10 [95% CI 1.15, 24.04], p=0.01). Six or more cycles of chemotherapy was superior to fewer cycles for

both PFS (aHR 0.17 [95% CI 0.10, 0.29]) and OS (aHR 0.12 [95% CI 0.07, 0.22]) with p-value < 0.001 for both PFS and OS. The Kaplan-Meier survival estimates demonstrated the prognostic utility of the IPI and aaIP for OS (p=0.002 and 0.030 respectively) and the IPI for PFS (p=0.002).

Conclusion: This study is a first from a high prevalence HIV area in KwaZulu-Natal, South Africa, and confirms the utility of the internationally accepted prognostic scoring systems in predicting survival in CD20 positive ARL in the local population.

Keywords

AIDS-Related Lymphoma (ARL); HIV-Associated Lymphoma (HAL); International Prognostic Score (IPI); Overall Survival (OS); Progression Free Survival (PFS)

List of Abbreviations

CR- Complete Response; PR- Partial Response; PFS- Progression Free Survival; OS- Overall Survival; ARL- AIDS Related Lymphoma; NHL- Non-Hodgkin lymphoma; HIV - Human Immunodeficiency Virus; DLBCL- Diffuse Large B Cell Lymphoma; BL- Burkitt Lymphoma; PL- Plasmablastic Lymphoma; PEL- Primary Effusion Lymphoma; CNS- Central Nervous System; PCNSL- Primary CNS Lymphoma; IPI- International Prognostic Index; aaIPI- Age Adjusted IPI; aOR- Adjusted Odds Ratio; aHR- Adjusted Hazard Ratio; DLBCL- Diffuse Large B Cell Lymphoma; ART- Antiretroviral Therapy; HAL- HIV Associated Lymphoma; LDH- Lactate dehydrogenase; CHOP- Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; ECOG- Eastern Cooperative Oncology Group; CNS- Central Nervous System; MINE- Mesna, Ifosfamide, Novantrone, Etoposide; VL- Viral Load

Introduction

Lymphomas that occur more frequently in people living with human immunodeficiency virus (HIV) are referred to as HIV-associated lymphomas (HAL). Three malignancies are considered AIDS-defining: high-grade non-Hodgkin lymphoma (NHL), Kaposi sarcoma and invasive cancer of the cervix. The AIDS-defining high-grade NHL are collectively called AIDS-related lymphomas (ARL) and are aggressive with diverse histologic characteristics [1]. These ARL include diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma (BL), plasmablastic lymphoma (PBL) and less commonly, primary CNS lymphoma (PCNSL) and primary effusion lymphoma (PEL) [2,3]. DLBCL and BL usually express CD20, and the other ARL are generally CD20 negative. The introduction of antiretroviral therapy (ART) in 1996 not only reduced the incidence of ARL but also improved outcomes [4-6]. Despite the widespread use of ART, ARL remains a common malignancy and a primary cause of AIDS-related malignant deaths [7-9]. South Africa is home to just over 20% of the global population living with HIV [10]. KwaZulu-Natal is a province in South Africa that has an HIV prevalence of 18% [11]. Ascertaining reliable and valid prognostic tools for rational utilization of scarce resources for the management of ARL is critical, particularly for these resource-limited settings.

Outcomes in ARL, both CD 20 positive and CD20 negative, are associated with characteristics of the host, malignancy, and HIV disease. The former two variables are incorporated into the well-established international prognostic index (IPI), which consists of the patient's age, performance status, lactate dehydrogenase (LDH) level, stage of lymphoma and the number of extranodal sites involved [12]. This index for aggressive lymphoma was initially derived from an HIV-negative cohort treated with combination chemotherapy [12]. This scoring system was subsequently validated for ARL treated with standard cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy as well as chemotherapy supplemented with CD20 monoclonal antibodies (rituximab) [13-15]. Another scoring index, the age-adjusted international prognostic index

(aaIPI), is a modified IPI score utilizing three variables of the IPI, viz. performance status, LDH level and stage of disease, strongly correlates with outcomes of ARL [12]. This score was validated in a pooled analysis of 1546 patients from 19 prospective trials conducted in the United States and Europe [16]. This study population included predominantly male patients, with a good median CD4 count, and differs from the stronger female representation and poorer CD4 count in ARL described in two South African studies as well as East Africa [17-19].

Unlike the IPI and aaIPI, the HIV-specific prognostic variables for ARL are less well-defined. Studies have variably analysed the prognostic significance of the viral load, CD4 count and history of prior AIDS-defining illness, showing poorer outcome with the latter two variables [20,21]. However, the significance of these variables has evolved over time with the use of ART, with less prognostic significance attributed to the CD4 count [22]. In this post-ART era, it is unclear if a specific ARL prognostic score would better determine prognosis in ARL than the IPI or aaIPI, and which variables would need to be included in such a score [23].

The therapeutic advances in ARL have resulted in outcomes comparable to HIV-negative patients, spurring the need to optimise current prognostic tools to improve management [13,20,24]. This is especially pertinent in countries with a high HIV prevalence where a significant portion of the health care budget is utilised in the management of ARL. The IPI and aaIPI prognostic scoring systems have not been validated in the local cohort or in the three other South African studies on ARL [17,18,25]. In KwaZulu-Natal, the significance of other lymphoma-related, or HIV-associated variables, including the CD4 count, concurrent ART, and viral load in CD20-positive ARL is also unknown. In these settings, accurate prognostic tools for an African cohort will guide the implementation of risk-adapted, cost-effective treatment strategies.

Methods

This was a retrospective review of patients with histologically confirmed CD20-positive ARL managed at King Edward VIII Hospital between January 2006 and December 2016. To be included, patients had to be over the age of 12 years, have received at least one cycle of CHOP chemotherapy, with or without rituximab (R), with curative intent, and have had at least four years of follow-up. Patients with Burkitt lymphoma were not included in this study, as these patients are treated with a more intensive chemotherapy protocol. Patients with primary central nervous system (CNS) lymphoma were also excluded from this analysis. Anonymized data from the patients' haematology charts was captured onto an Excel electronic spreadsheet. Laboratory data was further obtained from the National Health Laboratory Service laboratory information system. Data was exported into Stata 16 programme for analysis. The study protocol was approved by the Biomedical Research Ethics Council of the University of KwaZulu-Natal (BE043/17), and the study complied with the principles of the Declaration of Helsinki.

All patients in the study cohort were managed according to standard lymphoma treatment guidelines [26,27]. Between 2006 and 2013, CHOP was the main chemotherapy regimen. During 2013 local guidelines added rituximab to CHOP chemotherapy. CHOP and RCHOP were given at standard doses, except for prednisone, which was given at a dose of 60mg daily, orally for 8 days rather than 100mg daily for 5 days, according to the centre's practice. Here we report on the effect of established and individual prognostic variables on CR, 4-year OS and 4-year PFS. Patient-related variables considered for their prognostic value included age, gender, and Eastern Cooperative Oncology Group (ECOG) functional status. Tumor-related variables considered included B symptoms, Ann Arbor stage, use of rituximab, number of chemotherapy cycles, radiotherapy and CNS involvement. HIV-specific variables included baseline CD4 cell count, viral load, ART status, and timing of ART relative to initiation of chemotherapy. The cut-off for the age of 40 and CD4 of 100 cells/ μ L was chosen to allow for comparison with

existing data, which shows prognostic significance to these variables at these limits [16,2125,28]. The IPI score was categorized as low risk (0-2), and high risk (3-5). An aaIPI of 0-1 was considered low risk and a score of 2-3 as high risk.

CNS involvement was determined by imaging or cerebrospinal fluid examination using cytocentrifuge or flow cytometry. Response to therapy was assessed at mid-cycle and on completion of chemotherapy. CR was defined by the absence of disease assessed by clinical, radiological and laboratory measures. All records were available, except for viral load, where only 65 patients had information.

Statistical Analysis

Kaplan-Meier survival curves for OS and PFS at 4 years were compared for IPI and aaIPI (low versus high risk) using the log-rank test. Cox proportional hazards model was used to investigate the effects of prognostic variables on patients achieving OS and PFS during the study period. Logistic regression was used to determine the effects for the different prognostic variables in patients who achieved CR. Unadjusted and adjusted hazards and odds ratios are reported. All variables and outcome measures were evaluated on an intention-to-treat basis. All time-to-event analyses were measured from presentation to event or last recorded follow-up. P-values of <0.05 were considered statistically significant. Stata 16 was used for all data analyses [29].

Results

During the study time period, 157 ARL were managed at this hospital. There were 102 patients with CD20-positive ARL included in this analysis (histological subtypes were 70 DLBCL, 31 high-grade B cell lymphoma, and 1 high-grade B cell lymphoma not otherwise specified). 13 patients were excluded due to missing data (either histology or HIV results), 9 patients for receiving an alternative chemotherapy regimen, 5 patients who did not receive chemotherapy and 2 patients with primary effusion lymphoma. The data for 26 plasmablastic patients has

been published [30]. The chemotherapy regimens and 4-year survival outcomes are shown in **Figure 1**. From the 102 patients, 50% (n=51) were alive at 4 years, with 43% (n=44) showing no disease progression, 12% (n=12) demising and 38% (n=39) were lost to follow up during the 4 years. 64% (25/39) of the patients defaulting treatment were lost to follow-up within a year and none of these patients were in a CR at the time. There were 5 patients defaulting treatment between 12-24 months, and of the nine patients lost to follow-up after 2 years, 4 were treated with CHOP (2 with a partial response [PR] who chose not to continue further therapy, and 2 in CR) and 5 were treated with R-CHOP (all in CR). There were 3 patients who relapsed post first-line chemotherapy, with 2 receiving salvage therapy and the third patient was lost to follow-up immediately after documented relapse. For 21 patients receiving salvage therapy with mesna, ifosfamide, novantrone, etoposide (MINE), and/or high dose methotrexate and/or radiotherapy, 9 achieved a CR_s, 9 were lost to follow-up and 3 demised.




Figure 1: Treatment and outcomes for CD20 positive ARL.

For the patient and HIV prognostic variables shown in **Table 1**, the HIV viral load was the only variable that significantly affected the achievement of CR. Patients having undetectable viral loads of <50 copies/ml had a greater likelihood of CR (adjusted OR 6.10 [95% CI 1.55, 24.04]). Attaining a CR was significantly associated with improved PFS (HR = 0.08 [CI: 0.04, 0.16]; p-value <0.001) and OS (HR = 0.11 [CI: 0.06, 0.22]); p-value <0.001). At lymphoma diagnosis, 45% (n=46) of the patients were already on ART, 39% (n=40) initiated ART concurrently with chemotherapy and 16% (n=16) remained ART naïve during chemotherapy. Of the 86 patients who received concurrent ART with chemotherapy, 60% (n=50) achieved a CR and 25% (n=4) of the ART naïve group achieved a CR (p=0.994). Of the 16 ART naïve patients, 12 received CHOP. Four of these 12 patients attained a CR and two a PR, with five of these patients having an OS exceeding five years and the sixth patient defaulted therapy after 10 months. Of the remaining six patients on CHOP, one had disease progression, two demised after three months, and three defaulted follow-up, with OS ranging from 2 weeks to six months. Four ART naïve patients received R-CHOP; one had disease progression and died 25 months later, and the three remaining patients were lost to follow-up during chemotherapy (none in CR). Using the chi-squared test, the 4-year OS of 59% (46/86) for concurrent ART with chemotherapy and 31% (5/16) for those who remained ART naïve during chemotherapy, was not significantly associated with improved OS (p=0.111).

Table 1: Impact of patient and HIV variables on CR.

Predictor (%)	Unadjusted OR (95% CI)	CR (n = 56)	
		Adjusted OR (95% CI)	p-value
Age in years	<40 (55%)	ref	ref
	≥40 (45%)	1.32 (0.60, 2.91)	0.881
Gender	Female (54%)	ref	ref
	Male (46%)	1.03 (0.47, 2.26)	0.386
B symptoms	Absent (70%)	ref	ref
	Present (30%)	0.83 (0.35, 1.93)	0.798
ART timing	Pre-diagnosis (53%)	ref	ref
	Concurrent with chemotherapy (47%)	0.79 (0.33, 1.89)	0.994
CD4 count in cells/μL	< 100 (25%)	ref	ref
	≥ 100 (75%)	1.60 (0.66, 3.93)	0.885
VL	Undetectable or <50 copies/ml (49%)	8.21 (2.68, 25.17)	0.010
	≥50 copies/ml (51%)	ref	ref

Abbreviations: CR = complete response, OR = odds ratio, ART = antiretroviral therapy, VL = viral load.

For the 56 patients that attained a CR at the end of first line chemotherapy, two patients received 3 cycles, one had 4 cycles and another 5 cycles of chemotherapy (all four patients having refused additional chemotherapy). Of the 9 patients who received radiotherapy, 83% on CHOP (5/6) and 67% on R-CHOP (2/3) achieved a 4-year OS respectively. The impact of patient and HIV variables on PFS and OS are detailed in **Table 2** and lymphoma and treatment-related variables in **Table 3**.

Table 2: Impact of patient and HIV variables on outcome for CD20-positive ARL.

Predictor (%)	PFS			OS		
	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	p-value	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	p-value
Age in years						
<40 (55%)	ref	ref	ref	ref	ref	ref
≥40 (45%)	0.91 (0.54, 1.52)	1.02 (0.47, 2.22)	0.952	0.93 (0.53, 1.61)	0.95 (0.43, 2.10)	0.906
Gender						
Female (54%)	ref	ref	ref	ref	ref	ref
Male (46%)	0.77 (0.46, 1.29)	0.46 (0.21, 0.99)	0.048	0.78 (0.45, 1.37)	0.41 (0.19, 0.91)	0.028
B symptoms						
Absent (70%)	ref	ref	ref	ref	ref	ref
Present (30%)	1.04 (0.59, 1.81)	0.95 (0.41, 2.21)	0.901	1.18 (0.66, 2.12)	1.02 (0.43, 2.41)	0.959
ART						
Pre-diagnosis (53%)	ref	ref	ref	ref	ref	ref
Concurrent with chemotherapy (47%)	1.01 (0.56, 1.82)	0.84 (0.35, 2.04)	0.702	0.96 (0.51, 1.78)	0.85 (0.34, 2.11)	0.719
CD4 count in cells/μL						
< 100 (25%)	ref	ref	ref	ref	ref	ref
≥ 100 (75%)	0.81 (0.45, 1.44)	1.28 (0.38, 4.35)	0.694	0.93 (0.50, 1.74)	1.18 (0.35, 4.06)	0.787
VL						
Undetectable or <50 copies/ml (49%)	0.45 (0.23, 0.88)	0.45 (0.19, 1.07)	0.070	0.41 (0.21, 0.82)	0.43 (0.18, 1.05)	0.063
≥50 copies/ml (51%)	ref	ref	ref	ref	ref	ref

Abbreviations: ARL = AIDS related lymphoma, HR = hazard ratio, CR = complete response, PFS = progression free survival, OS = overall survival, ART = antiretroviral therapy, VL = viral load.

Of the total cohort, 9% (n=9) received radiotherapy; 4 patients with bulky disease, 1 patient with a tonsillar relapse (who received salvage chemotherapy and radiotherapy) and progressive disease treated with salvage chemotherapy in the remaining four patients. A third of the study patients who received radiotherapy (3/9) had a good response with the sole addition of curative dose radiotherapy to 1st line chemotherapy, converting partial responses to CR in all three patients (all 3 had bulky disease). There was a 78% (7/9) 4-year OS for patients receiving radiotherapy compared with 47% (44/93) for patients who did not receive radiotherapy (p=0.071).

Table 3: Lymphoma and treatment related variables in CD20-positive ARL.

Predictor (%)	PFS			OS		
	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	p-value	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	p-value
CNS involvement by lymphoma	ref	ref	ref	ref	ref	ref
Absent (93%)	1.20	1.04	0.951	1.04 (0.38)	1.58	0.444
Present (7%)	(0.48, 3.00)	(0.35, 3.10)			(0.49, 5.04)	
Rituximab use	ref	ref	ref	ref	ref	ref
No (49%)						
Yes (51%)	0.81	0.76	0.289	1.04	0.89	0.675
	(0.48, 1.36)	(0.45, 1.27)		(0.60, 1.80)	(0.51, 1.55)	
Radiotherapy use	ref	ref	ref	ref	ref	ref
No (91%)						
Yes (9%)	0.86	0.70	0.519	0.33	0.23	0.071
	(0.34, 2.16)	(0.23, 2.09)		(0.08, 1.37)	(0.05, 1.14)	
Number of chemotherapy cycles	ref	ref	ref	ref	ref	ref
< 6 (30%)		0.17				
6-8 (70%)	0.16	(0.10, 0.29)	<0.001	0.13	0.12	<0.001
	(0.10, 0.29)			(0.07, 0.23)	(0.07, 0.22)	

Abbreviations: ARL = AIDS related lymphoma, HR = hazard ratio, ARL = AIDS related lymphoma, CR = complete response, PFS = Progression free survival, OS = overall survival, CNS = central nervous system.

There was no significant association between individual prognostic variables of the aaIPI and OS or PFS (Table 4). However, the IPI and aaIPI significantly correlated with OS (Figure 2 and Figure 3 respectively) and the IPI also significantly correlated with PFS and not OS (Figure 2).




Figure 2: Kaplan Meier survival estimates: IPI for for PFS, p-value = 0.002 (left) and IPI for OS, p-value = 0.002 (right).




Figure 3: Kapan Meier survival estimates: aaIPI for PFS, p-value = 0.266 (left) and aaIPI for OS, p-value = 0.030 (right).

Table 4: aaIPI prognostic variables on outcome of CD20-positive ARL.

Predictor (%)	PFS			OS		
	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	p-value	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	p-value
Ann Arbor stage	ref	ref	ref	ref	ref	ref
Early—II/III (55%)	1.92	1.93	ref	2.05	2.04	0.065
Late—III/IV (45%)	(1.14, 3.23)	(0.95, 3.90)	0.067	(1.17, 3.59)	(0.96, 4.37)	
ECOG PS	ref	Ref	ref	ref	ref	ref
< 2 (32%)	1.66	1.05	0.899	1.70	1.03 (0.43, 2.46)	0.941
≥ 2 (68%)	(0.91, 3.04)	(0.47, 2.35)		(0.89, 3.25)		
LDH increased	ref	Ref	ref	ref	ref	ref
No (4%)	0.71	0.56	0.340	1.01	0.77	0.727
Yes (96%)	(0.22, 2.26)	(0.17, 1.85)		(0.24, 4.14)	(0.18, 3.27)	

Abbreviations: ARL = AIDS related lymphoma, aaIPI = age adjusted International Prognostic Index, CR = complete response, PFS = progression free survival, OS = overall survival, HR = hazard ratio, ECOG PS = Eastern Cooperative Oncology group performance status, LDH = lactate dehydrogenase.

Discussion

Better HIV control in ARL has allowed for chemotherapy intensification with monoclonal antibodies similar to HIV-negative patients with lymphoma, and this is the first study from South Africa describing the prognostic significance of rituximab use in ARL. This study's 4-year OS of 50% is within the reported 5-year survival of 46-55% for ARL [20,24] and comparable to the reported 46% 5-year survival in another South African study [18]. This improved 4-year survival in the ART era, compared with the 11-month median OS described in Gauteng, South Africa with 85% of the cohort not on ART [17], highlights the need for an accurate prognostic system to guide therapy in ARL.

The CR for the study cohort of 55% is at the lower spectrum of reported CR; 65% is described by Miralles et al in the multicentre Spanish study [20] and 58-77% in American and European studies [31,32]. However, this CR correlated with 4-year OS and PFS in our cohort. This finding is in accordance with the positive predictive value of the CR for OS found in a retrospective British cohort [13].

The only patient-related variable that correlated with survival, was gender, with males having both improved PFS and OS. This prognostic significance of gender has been confirmed by other studies in Africa, including South Africa [18,33]. These findings, however, contrast with the poorer outcome shown for male patients in Zimbabwe, and lack of significance for gender in studies outside of Africa [28]. Whether gender remains a unique prognostic variable for an African cohort in the ART era warrants further study.

There was no improvement in 4-year OS in patients who received ART with chemotherapy compared with those who remained ART naïve during chemotherapy ($p=0.111$). This result contrasts with the Lim et al [21] analysis which showed that median survival increased significantly from 8.3 months in ART naïve patients to 43.2 months for those on ART. Our study findings also contrast with an African study from Uganda which found similar survival outcomes in ARL treated with concurrent ART and chemotherapy compared with HIV-negative lymphoma patients, but an almost 9-fold increase in mortality in ARL patients not taking ART compared with HIV-negative patients [33]. Barta et al demonstrated that survival increased from 24% pre-ART to 67% in the ART era [22]. All 3 studies show a clear survival benefit to ART, which is not evident in our cohort. A similarly matched South African cohort to our study cohort also showed poor outcome pre-ART [17]. This lack of prognostic significance in our study is therefore most likely due to the smaller number of patients not on ART ($n=16$), rather than a true lack of significance.

Although a low or undetectable viral load in our study significantly affected CR ($p=0.01$), this did not translate to a

significantly improved FPS or OS. Our findings are similar to a Spanish study in terms of viral load correlating with CR but did not match the correlation with virological response and improved OS seen in this Spanish cohort [32]. The lack of impact on the OS in our cohort may be due to small sample size, or lymphocyte dysregulation, even whilst on ART being driven by immune activation [34,35] rather than HIV viral replication [36,37]. This could negate the benefit of a low or undetectable viral load on OS.

The CD4 count was not associated with improved OS ($p=0.787$), and this shift away from the significance of the immune status reflected by the CD4 count in the ART era has been well documented [13,22,38]. A retrospective analysis of ARL patients pre and post-ART, found that a low CD4 count of < 100 cells/mL was associated with poorer survival only in the pre-ART era [21]. However, the prognostic value of the CD4 cell count in the post-ART era is not entirely lost. When used in a composite score with the viral load and past history of AIDS-defining illness, it showed a strong association with mortality [23].

There was no association between the timing of ART and survival in our cohort (aHR 0.85 [95% CI 0.34, 2.11] $p=0.719$), which is borne out by a Chinese study on 100 patients with ARL [39]. However, this is contradictory to the multicentre study in sub-Saharan Africa by Gopal et al [40] and a Brazilian study [41] which found a significantly lower OS in ARL diagnosed in patients already on ART. A German study also found poorer OS in ARL patients already on ART at lymphoma diagnosis compared with ART initiated post lymphoma diagnosis [42]. The conflicting results on the prognostic significance of the timing of ART in ARL is worthy of further study.

In this study, there was no improvement in outcome with the use of rituximab, in contrast to the clearly proven benefit in multiple international studies [16,42-44]. Unsurprisingly, patients who received 6-8 cycles of chemotherapy had a significantly better outcome than patients receiving < 6 cycles of chemotherapy ($p<0.001$). The FLYER trial demonstrated non-inferiority of 4

cycles of R-CHOP and 2 additional rituximab doses compared to 6 cycles of R-CHOP [45]. However, this group included only HIV-negative patients with DLBCL and an excellent aaIPI of 0. In our cohort, only 1 patient had an aaIPI of 0. This patient had progressive disease on R-CHOP and required radiotherapy and salvage chemotherapy to attain a 4-year OS. Compatible with our study findings, another cohort in Africa found that patients with ARL who received < 3 cycles of chemotherapy had a significant increase in mortality at 18 months [28]. In the absence of randomised trials, and noting that most patients with ARL have an aaIPI >0, our findings would support current guidelines of 6-8 cycles of R-chemotherapy in CD20 positive ARL [46,47].

Although the numbers are small, with only 9% receiving radiotherapy, the trend toward significance in survival is different to another small study on consolidative radiotherapy in HIV DLBCL, which found no significant difference in OS in patients who received radiotherapy [48]. Unlike this latter study, the indications for radiotherapy in our study were more diverse and included bulky disease, relapse and progressive disease. For the only 2 patients who received radiotherapy but did not reach 4-year OS, both had high-risk IPI of 4, with one patient having additional risk with testicular involvement. There is limited literature on the value of radiotherapy in ARL apart from primary central nervous system lymphoma. Radiotherapy as a therapeutic tool in ARL management merits further investigation.

Both the IPI and aaIPI were associated with OS. The IPI also correlated with PFS (**Figure 2**). These findings are supported by other studies [49,50,51]. However, unlike the latter studies, the individual components in the aaIPI in our cohort did not correlate with outcome, either in univariate or multivariate analysis. The skewed LDH results, with 96% of the study cohort having a raised LDH, would also account for it not being of predictive value.

Study Limitations

The retrospective design of the study limited the nature and extent of patient and laboratory information available (viral load was only available for 65 patients). Data related to ART regimens and prior diagnosis of AIDS or opportunistic infection were not available for all patients and the significance of these variables could not be determined. The sample size, in assessing the value of rituximab and ART, was a further limitation, that will be addressed in a local, prospective study. The large number of patients lost to follow-up (38%) was a further limitation.

Conclusion

This study demonstrates reasonable 4-year survival outcomes with combination chemotherapy and ART in CD20-positive ARL. It validates the utility of the IPI and aaIPI in determining prognosis in ARL in an HIV endemic province in South Africa. Further studies are required to explore the prognostic significance of ART timing, gender and the feasibility of individualized chemotherapy as stratified by prognostic factors.

References

1. World Health Organization (WHO). AIDS: 1987 revision of CDC/WHO case definition. *Bulletin of the World Health Organization*. 1988; 66: 259-263.
2. Brunberg U, Hentrich M, Hoffmann C, Wolf T, Huebel K. HIV-associated malignant lymphoma. *Oncology Research and Treatment*. 2017; 40: 82-87.
3. Gabarre J, Raphael M, Lepage E, Martin A, Oksenhendler E, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. *The American Journal of Medicine*. 2001; 111: 704-711.
4. Cobucci RN, Lima PH, De Souza PC, Costa VV, de Mesquita Cornetta MD, et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. *Journal of Infection and Public Health*. 2015; 8: 1-10.

5. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. *Blood, The Journal of the American Society of Hematology*. 2001; 98: 2339-2344.
6. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. *Blood, The Journal of the American Society of Hematology*. 2001; 98: 3406-3412.
7. Antiretroviral Therapy Cohort Collaboration. D'Arminio MA, Sabin CA, Phillips A, Sterne J, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. *Archives of Internal Medicine*. 2005; 165: 416-423.
8. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. *Annals of Internal Medicine*. 2015; 163: 507-518.
9. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2008; 48: 590-598.
10. Global HIV and AIDS statistics. Available online at: <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics>
11. Statistics South Africa. Mid-year population estimates. 2019. Pretoria: 2019
12. Shipp MA. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. *N Engl J Med*. 1993; 329: 987-994.
13. Coutinho R, Pria AD, Gandhi S, Bailey K, Fields P, et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. *Aids*. 2014; 28: 689-697.
14. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, et al. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's

- lymphoma treated with CHOP. A multivariate study of 46 patients. *Haematologica*. 1998; 83: 508-513.
15. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. *Journal of Clinical Oncology*. 2010; 28: 2373-2380.
 16. Barta SK, Xue X, Wang D, Tamari R, Lee JY, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. *Blood, The Journal of the American Society of Hematology*. 2013; 122: 3251-3262
 17. Patel M, Philip V, Turton D, Omar T, Kosheva S, et al. The impact of HIV on non-Hodgkin's lymphoma at Chris Hani Baragwanath Hospital. *Haematologica-The Hematology Journal*. 2007; 92; 273-273.
 18. Magangane PS, Mohamed Z, Naidoo R. Diffuse large B-cell lymphoma in a high human immunodeficiency virus (HIV) prevalence, low-resource setting. *SA Journal of Oncology*. 2020; 4: 1-7.
 19. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, et al. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. *Journal of Clinical Oncology*. 2009; 27: 3480-3488.
 20. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, et al. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2007; 44: 167-173.
 21. Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. *Journal of Clinical Oncology*. 2005; 23: 8477-8482.
 22. Barta SK, Samuel MS, Xue X, Wang D, Lee JY, et al. Changes in the influence of lymphoma-and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. *Annals of Oncology*. 2015; 26: 958-966

23. Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, et al. A new prognostic score for AIDS-related lymphomas in the rituximab era. *Haematologica*. 2014; 99: 1731-1737.
24. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. *Antiviral Therapy*. 2009; 14: 1065-1074.
25. De Witt P, Maartens DJ, Uldrick TS, Sissolak G. Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll-out of combination antiretroviral therapy in South Africa. *Journal of Acquired Immune Deficiency Syndromes*. 2013; 64: 66-73.
26. Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2012; 23: vii78-82
27. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. *J Natl Compr Canc Netw*. 2010; 8: 288-334.
28. Manyau MC, Mudzviti T, Rusakaniko S, Mberi ET, Maponga CC, et al. Survival of HIV-infected patients with high-grade non-Hodgkin's lymphomas: A retrospective study of experiences in Zimbabwe. *Plos one*. 2020; 15: e0239344
29. StataCorp. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC. 2019.
30. Rapiti N, Peer N, Abdelatif N, Rapiti P, Moosa Y. HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa. *HIV Med*. 2022; 1–12.
31. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. *Journal of Clinical Oncology*. 2006; 24: 4123-4128.
32. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large

- B-cell lymphoma: results of a phase II trial. *British Journal of Haematology*. 2008; 140: 411-419.
33. Bateganya MH, Stanaway J, Brentlinger PE, Magaret AS, Wald A, et al. Predictors of survival after a diagnosis of non-Hodgkin's lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment. *Journal of Acquired Immune Deficiency Syndromes* (1999). 2011; 56: 312-319.
 34. Vendrame E, Hussain SK, Breen EC, Magpantay LI, Widney DP, et al. Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. *Cancer Epidemiology and Prevention Biomarkers*. 2014; 23: 343-339.
 35. Titanji K, Chiodi F, Bellocco R, Schepis D, Osorio L, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. *Aids*. 2005; 19: 1947-1955.
 36. Isgro A, Leti W, DeSantis W, Marziali M, Esposito A, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. *Clinical Infectious Diseases*. 2008; 46: 1902-1910.
 37. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. *Blood, The Journal of the American Society of Hematology*. 2011; 117: 5142-5151.
 38. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. *Annals of Internal Medicine*. 2005; 143: 265-273.
 39. Wu D, Chen C, Zhang M, Li Z, Wang S, et al. The clinical features and prognosis of 100 AIDS-related lymphoma cases. *Scientific Reports*. 2019; 9: 1-7.
 40. Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. *Journal of the National Cancer Institute*. 2013; 105: 1221-1229.

41. Cuellar LE, Anampa-Guzmán A, Holguín AM, Velarde J, Portillo-Alvarez D, et al. Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience. *Infectious Agents and Cancer*. 2018; 13: 1-6.
42. Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, et al. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. *Aids*. 2012; 26: 457-464.
43. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. *Blood*. 2005; 105: 1891-1897.
44. Baptista MJ, Garcia O, Morgades M, Gonzalez-Barca E, Miralles P, et al. HIV-infection impact on clinical—biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. *Aids*. 2015; 29: 811-818.
45. Poeschel V, Held G, Ziepert M, Altmann B, Witzens-Harig M, et al. Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B-cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the FLYER trial of the Dshnhl/GLA. *Blood*. 2018; 132: 781.
46. Hentrich M, Hoffmann C, Mosthaf F, Müller M, Siehl J, et al. Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG). *Annals of hematology*. 2014; 93: 913-921.
47. Writing Group, Bower M, Palfreeman A, Alfa-Wali M, Bunker C, et al. British HIV Association guidelines for HIV-associated malignancies 2014. *HIV Medicine*. 2014; 15: 1-92.
48. Casimiro LC, Mauro GP, Medici CT, Weltman E. Survival and consolidative radiotherapy in patients living with HIV and treated for diffuse large B-cell lymphoma. *Reports of Practical Oncology and Radiotherapy*. 2020; 25: 956-960.

49. Rossi G, Donisi A, Casari S, Re A, Cadeo G, et al. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus—related systemic non-Hodgkin lymphoma. *Cancer: Interdisciplinary International Journal of the American Cancer Society*. 1999; 86: 2391-2397.
50. Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, et al. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. *Aids*. 2017; 31: 2493-2501.
51. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. *AIDS (London, England)*. 2009; 23: 2029-2037.